CEPI

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
Monday, December 5, 2022
Euronext Paris, European, BLA, Infection, CEPI, EMA, Immunization, Vaccination, Mortality, VLA, Antibody, FDA, Marketing, Safety, Priority, Headache, Nausea, Vaccine, Human, Lyme disease, Fever, Interest group, Food and Drug Administration, LMIC, Disease, Ageing, Rash, SAE, Public health, Genome, Aedes, Alphavirus, Fast track (FDA), File, Dietary supplement, Pharmaceutical industry, Instituto Butantan, Valneva SE, CHIKV, Chikungunya

The antibody persistence trial enrolled 363 healthy adult participants and followed them from month 6 after vaccination to month 12.

Key Points: 
  • The antibody persistence trial enrolled 363 healthy adult participants and followed them from month 6 after vaccination to month 12.
  • These antibody levels confirm the antibody persistence profile observed in an earlier study3.
  • The antibody persistence was similar in older adults aged ≥65 years, who retained neutralizing antibody titers comparable to younger adults throughout the follow-up.
  • VLA1553 is a live-attenuated, single dose vaccine candidate targeting the chikungunya virus, which has spread to over 100 countries.

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Nipah virus, Interim, Coalition for Epidemic Preparedness Innovations, Infection, Disease, Government of Canada, COVID-19, G7, Risk, Chikungunya, Cytomegalovirus, Virus, National Research Council, Partnership, Coronavirus, Epidemic, Multimedia, Vaccine, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Glioblastoma, Middle East respiratory syndrome–related coronavirus, Omicron, Hepatitis B, Lassa mammarenavirus, Science, VLP, CEPI, CMV, Severe acute respiratory syndrome coronavirus, Immunity, Nature, COVAX, Immune system, NRC, Rift Valley fever, Pandemic, Research, Annual report, Human coronavirus 229E, Public sector, VBI, News, Safety, G20, GBM, Coalition, Animal, Pharmaceutical industry

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.

Key Points: 
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the Coronavirus X potential of VBIs technology.
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shekel, InSight, CPT, Marketing, Adult, Net, High-net-worth individual, Overalls, HBV, Partnership, Nasdaq, VBI, GBM, Hepatitis B, G&A, CDC, Glioblastoma, R, CEPI, United Kingdom, Mission statement, Israeli new shekel, Survival, Vaccination, Government, Disease, Research and development, GAAP, Medicare, Awareness, Patient, CEO, Administration, Medicaid, Vaccine, Insurance, Pharmaceutical industry, Financial services, European

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
  • Revenue: Revenue, net for the third quarter of 2022 was $0.3 million, compared to $0.1 million for the same period in 2021.
  • Cost of Revenue: Cost of revenues was $2.7 million in the third quarter of 2022 as compared to $2.5 million in the third quarter of 2021.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress

Retrieved on: 
Thursday, November 3, 2022
Severe acute respiratory syndrome coronavirus 2, Company, Private Securities Litigation Reform Act, Research, Biology, GLOBE, Epidemic, Human, Intellectual property, Exosome, Vaccine, Immunotherapy, Liver disease, Colorectal cancer, CEO, Infection, U.S. Securities and Exchange Commission, Clinical trial, NASDAQ, Partnership, Lonza, Liver, Security (finance), SEC, Society, SITC, Patient, CEPI, Coalition, Society for Immunotherapy of Cancer, Program, Pharmaceutical industry, Fine chemical, Cryptocurrency

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today reported third quarter 2022 financial results and recent operational progress.

Key Points: 
  • Present new preclinical data for macrophage targeting programs exoASO-STAT6 and exoASO-C/EBP at the Society for Immunotherapy of Cancer (SITC) in November 2022.
  • Total revenues for the quarter ended September 30, 2022 were $0.5 million, compared to $1.2 million for the same period in 2021.
  • General and administrative expenses were $6.6 million for the quarter ended September 30, 2022, compared to $7.2 million for the same period in 2021.
  • As of September 30, 2022, Codiak had cash, cash equivalents, and marketable securities of approximately $51.8 million.

Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 3, 2022
TSNA, RNA transfection, Association, KRAS, CORAL, Research, National Institute, Annual report, U.S. Securities and Exchange Commission, Clinical trial, CMC, ICB, Virology, Immune system, Technology, Collaboration, Coalition, Infection, Program, Degenerative disease, GLOBE, Epidemic, IND, Mutation, HIV, Gilead Sciences, Vaccine, Security (finance), Patient, NIAID, Viral disease, ESMO, SLATE, CRC, CD8, COVID-19, Coalition for Epidemic Preparedness Innovations, MRR, Data, Volunteering, Immunotherapy, Survival, CEPI, Bill, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Chemistry, MOS, National Institute of Allergy and Infectious Diseases, HLA, NSCLC, Bill & Melinda Gates Foundation, Trial of the century, Cryptocurrency, Pharmaceutical industry, Nature Medicine, Gritstone

EMERYVILLE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the third quarter ended September 30, 2022 and reviewed business highlights.

Key Points: 
  • These results are consistent with prior results from GRANITE in advanced colorectal cancer patients.
  • In August 2022, interim results from the Phase 1/2 trial of GRANITE were published in Nature Medicine ( here ).
  • In September 2022, Gritstone presented positive data from a Phase 1/2 study evaluating KRAS-directed SLATE at ESMO.
  • In October 2022, Gritstone shared interim positive results from the ongoing Phase 1 CORAL-BOOST (NCT05148962) and CORAL-CEPI (NCT05435027) trials at a company-sponsored webinar .

Sia Partners Accelerates in the Life Sciences Sector with the Acquisition of Latham BioPharm Group

Retrieved on: 
Thursday, November 3, 2022
Public Policy, Government, Medical Devices, Health, Animal Welfare, Pharmaceutical, Biotechnology, Growth, Heart, Risk and strategic consulting, New product development, United States Department of Defense, COVID-19, Sia, Control, European, Partner, LBG, Sia Partners, Information, DTRA, DARPA, CMC, Acquisition, Chemistry, Non-governmental organization, NIH, Consultant, CEPI, BARDA, Industrial design, Pharmaceutical industry, Fine chemical

Sia Partners is accelerating its growth with the launch of a division dedicated to Life Science Consulting, thanks to the acquisition of Latham BioPharm Group (LBG), a comprehensive team of nearly 60 life science consultants with recognized global Life Sciences expertise, founded in 1996.

Key Points: 
  • Sia Partners is accelerating its growth with the launch of a division dedicated to Life Science Consulting, thanks to the acquisition of Latham BioPharm Group (LBG), a comprehensive team of nearly 60 life science consultants with recognized global Life Sciences expertise, founded in 1996.
  • The wave of scientific innovation we are experiencing is unprecedented, particularly at the intersection of the Life Sciences and Information Technologies.
  • Peter Latham will head Sia Partners new global Life Science division within the group's ExCom, and Joshua Speidel and Michael McGinnis will be appointed Partners within the group.
  • Sia Partners, supported by a growth of +45%, has just passed the mark of 2,800 employees worldwide, spread across 40 offices.

EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

Retrieved on: 
Monday, October 31, 2022
Biotechnology, DPT, CDMO, MERS, Research, Program, Influenza, Industry, SARS, Active ingredient, Infection, CEPI, Technology, Coalition, Epidemic, OMV, Epitope, Vaccine, Severe acute respiratory syndrome coronavirus 2, COVID-19, Therapy, Pharmaceutical industry

PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic PreparednessInnovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.

Key Points: 
  • PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic PreparednessInnovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
  • EpiVax will be carrying out the vaccine epitope selection portion of the collaboration using their comprehensive in silico vaccine design toolkit "iVAX" .
  • EpiVax joins forces with Intravacc and CEPI to accelerate development of a universal betacoronavirus vaccine.
  • In addition to vaccine epitope selection, EpiVax will also develop multiple designs, and will validate these in silico constructs in vivo with HLA-transgenic mice.

EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine

Retrieved on: 
Monday, October 31, 2022
Biotechnology, DPT, CDMO, MERS, Research, Program, Influenza, Industry, SARS, Active ingredient, Infection, CEPI, Technology, Coalition, Epidemic, OMV, Epitope, Vaccine, Severe acute respiratory syndrome coronavirus 2, COVID-19, Therapy

PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic PreparednessInnovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.

Key Points: 
  • PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic PreparednessInnovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
  • EpiVax will be carrying out the vaccine epitope selection portion of the collaboration using their comprehensive in silico vaccine design toolkit "iVAX" .
  • In addition to vaccine epitope selection, EpiVax will also develop multiple designs, and will validate these in silico constructs in vivo with HLA-transgenic mice.
  • EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design.

Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases

Retrieved on: 
Tuesday, October 25, 2022
U.S. Securities and Exchange Commission, Time, Degenerative disease, EVP, ET, Infection, Virus, Vaccination, GLOBE, Date, Annual report, Immune system, COVID-19, Epidemic, Bill & Melinda Gates Foundation, CEPI, National Institute, Vaccine, RNA, Severe acute respiratory syndrome coronavirus 2, Bill, Convalescence, AES, Program, COVID-19 vaccine, Immunoglobulin G, National Institute of Allergy and Infectious Diseases, Coalition for Epidemic Preparedness Innovations, Security (finance), Coalition, RNA transfection, NAB, Volunteering, NIAID, Pharmaceutical industry, Online shopping, VOC, Gritstone

EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced positive Phase 1 results from its ongoing CORAL-BOOST and CORAL-CEPI trials evaluating its self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2. The results, which will be presented by the studies’ lead investigators in a company-sponsored webinar at 8:00 am ET today, collectively demonstrate Gritstone’s samRNA vaccine candidates are well-tolerated and capable of driving strong, potentially durable and broad immunogenicity across several subject populations and settings. These results build upon previous preclinical and clinical findings and support the application of Gritstone’s samRNA platform for the prevention and treatment of infectious diseases.

Key Points: 
  • These results build upon previous preclinical and clinical findings and support the application of Gritstones samRNA platform for the prevention and treatment of infectious diseases.
  • The study is being run in South Africa with support from the Coalition for Epidemic Preparedness Innovations (CEPI).
  • Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the worlds most potent vaccines.
  • The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof.

SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

Retrieved on: 
Tuesday, October 25, 2022
Lassa mammarenavirus, Bill, RNA transfection, Pandemic, Second, CEPI, GIA, Virus, CMV, Ministry of Health and Welfare (South Korea), JEV, Vaccine, Organization, Foundation, RSV, SK, RNA, MOHW, Equitable, Partnership, Technology, Infection, Epidemic, Company, Public health, Health, CEO, Ministry, Park Min-soo, Coalition, Control, COVID-19, USD, Policy, Pharmaceutical industry

USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.

Key Points: 
  • USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.
  • Under the agreement, SK bioscience will receive up to 140 million USD in R&D expenses from CEPI.
  • Earlier, SK bioscience had the partnership with the Bill & Melinda Gates Foundation in order to build the mRNA vaccine platform.
  • CEPI and SK bioscience are committed to enabling global equitable access to the vaccines they develop.